CMS vs. The Coalition: A High-Stakes Battle Over Remote Care's Future

GREENVILLE, SC – July 23, 2026 – A significant policy showdown is brewing over the future of remote healthcare for America's seniors. The Centers for Medicare and Medicaid Services (CMS) has proposed a slate of aggressive new rules for its 2027 Physician Fee Schedule, aimed at reining in the booming field of Remote Patient Monitoring (RPM). But a newly formed coalition of providers and technology companies, rallying under the banner #SaveRemoteMonitoring, is firing back, arguing the proposals are a sledgehammer approach that will demolish a vital patient lifeline.

At the heart of this conflict is a fundamental disagreement over how to manage one of the most promising advances in preventive care in years. On one side, CMS sees a rapidly growing service that demands stricter "guardrails" to ensure program integrity. On the other, providers see a clumsy regulatory overreach that will punish the compliant, strand the vulnerable, and ultimately undo years of progress in digital health. The debate, which will come to a head as the public comment period closes on September 14, will define the operational and financial viability of remote care for millions.

The Four Pillars of Contention

Leading the charge against the proposed rule (CMS-1848-P) is the Save Remote Monitoring Coalition, launched by ChartSpan, a major managed service provider in the chronic care space. The coalition is targeting four specific provisions they claim will cripple the RPM ecosystem.

The most disruptive proposal would require that all clinical staff performing monitoring services be direct employees of the billing practice. This effectively outlaws the third-party partnership model that has allowed thousands of smaller and rural practices to offer RPM. The irony, as the coalition points out, is that CMS itself explicitly authorized this exact model in its 2021 fee schedule. Reversing this position, they argue, would not stop determined fraudsters but would sever the operational support that understaffed clinics rely on. "The result would be fewer monitored patients, not fewer fraudulent claims," the coalition stated in its announcement.

Second, CMS wants to mandate a separately billable, face-to-face visit before a patient can even begin remote monitoring. While intended to confirm medical necessity, critics argue this creates a significant barrier for the very people RPM was designed to help: the homebound, the frail, and those with limited mobility or transportation. "A physician's order and documented patient consent already establish medical necessity," the coalition argues, framing the requirement as a care-delaying tactic that, for many, amounts to care denial.

Third, the agency proposes to devalue the reimbursement codes for device supply and setup, based on a theory that the hardware now costs less. Providers counter that this view ignores the bundled real-world costs of delivering a reliable service, which include not just the FDA-cleared device but also cellular connectivity, secure logistics, and the clinical team reviewing the data. "Cutting payment below the cost of the service does not make programs more efficient," a coalition spokesperson noted. "It closes them."

Finally, CMS is floating the idea of bundling the seventeen distinct CPT codes for RPM into just four new G-codes. This move would obscure the different types of work involved—setup, device management, and clinical treatment—and destabilize the billing processes that practices have spent years perfecting. According to industry analysts, this simplifies billing for CMS but creates chaos for providers, addressing no documented problem while threatening the economic stability of every compliant RPM program.

A Dispute Over Data and Intent

The justification for these sweeping changes hinges on oversight work from the HHS Office of Inspector General (OIG), particularly a September 2024 report on RPM utilization. CMS has interpreted the report's findings as a call for tighter controls. However, the Save Remote Monitoring Coalition contends the agency is misreading the evidence.

The OIG report noted that 43 percent of enrolled patients did not receive all three components of the service—setup, device supply, and treatment management—within the study's fixed window. The coalition argues this figure is not evidence of fraud, but a reflection of clinical reality: patients enroll mid-period, discontinue monitoring when their condition stabilizes, or only require certain components of the service. The OIG itself framed this as a number that "raises questions worth studying," not a definitive finding of improper care.

Similarly, the OIG's alarm over a tenfold growth in RPM enrollment between 2019 and 2022 is, in the eyes of providers, a sign of a benefit's successful adoption among an aging population with rising rates of chronic disease. The coalition's position is clear: use the data to perform aggressive, targeted enforcement against genuine bad actors—audit enrollment mills and prosecute those who bill for services never rendered—rather than dismantling the structure that enables legitimate care.

A Turning Point for Digital Health

This regulatory clash marks a dramatic reversal from just a year ago. The 2026 Physician Fee Schedule was lauded for expanding RPM access, notably by removing the "16-day cliff" that required a high frequency of data transmission to qualify for payment. That move was seen as a pragmatic acknowledgment of real-world patient adherence. The 2027 proposals, described by one legal analyst as containing "real surprises for digital health innovators," swing the pendulum hard in the other direction, from expansion to restriction.

The outcome will have profound consequences. If the rules are finalized as proposed, the RPM market could see significant consolidation. Large, well-resourced health systems with in-house monitoring teams may inherit the market, while smaller practices and the third-party vendors that support them face an existential threat. For the millions of Medicare patients managing conditions like hypertension, heart failure, and diabetes from home, the stakes are even higher. As providers and technology firms scramble to submit their evidence before the September deadline, the future of this transformative care model hangs in the balance, caught between the imperatives of innovation and regulation.